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BACKGROUND: Men diagnosed with localised prostate cancer (LPC) face difficult choices between treatment options that can cause
persistent problems with sexual, urinary and bowel function. Controlled trial evidence about the survival benefits of the full range of
treatment alternatives is limited, and patients’ views on the survival gains that might justify these problems have not been quantified.
METHODS: A discrete choice experiment (DCE) was administered in a random subsample (n¼ 357, stratified by treatment) of a
population-based sample (n¼ 1381) of men, recurrence-free 3 years after diagnosis of LPC, and 65 age-matched controls (without
prostate cancer). Survival gains needed to justify persistent problems were estimated by substituting side effect and survival
parameters from the DCE into an equation for compensating variation (adapted from welfare economics).
RESULTS: Median (2.5, 97.5 centiles) survival benefits needed to justify severe erectile dysfunction and severe loss of libido were 4.0
(3.4, 4.6) and 5.0 (4.9, 5.2) months. These problems were common, particularly after androgen deprivation therapy (ADT): 40 and
41% overall (n¼ 1381) and 88 and 78% in the ADT group (n¼ 33). Urinary leakage (most prevalent after radical prostatectomy
(n¼ 839, mild 41%, severe 18%)) needed 4.2 (4.1, 4.3) and 27.7 (26.9, 28.5) months survival benefit, respectively. Mild bowel
problems (most prevalent (30%) after external beam radiotherapy (n¼ 106)) needed 6.2 (6.1, 6.4) months survival benefit.
CONCLUSION: Emerging evidence about survival benefits can be assessed against these patient-based benchmarks. Considerable
variation in trade-offs among individuals underlines the need to inform patients of long-term consequences and incorporate patient
preferences into treatment decisions.
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Men diagnosed with localised prostate cancer (LPC) face difficult
treatment decisions. Although the eradication of cancer is a
major issue for most men (Zeliadt et al, 2006), controlled trial
evidence about the survival benefits of the full range of treatment
alternatives is limited (Wilt et al, 2008) and likely to remain so for
some time. Survival benefits are offset by treatment complica-
tions, including problems with sexual, urinary and bowel
function (Potosky et al, 2004; Sanda et al, 2008; Parker et al,
2009; Smith et al, 2009), issues considered important by patients
and their partners (Zeliadt et al, 2006; van Tol-Geerdink et al,
2006a). Limitations in the evidence and personalised trade-offs
between quantity and quality of life mean that no one therapy can
be considered the preferred treatment for all men (Wilt et al,
2008). Although optimal treatment is influenced by tumour and
patient characteristics (Sommers et al, 2007), patient preference
is also an important factor (National Health and Medical
Research Council (NHMRC), 2003; National Comprehensive
Cancer Network, 2004; Zeliadt et al, 2006; Sommers et al,
2007). Many patients would like to be involved in decision
making (Davison et al, 2004; van Tol-Geerdink et al, 2006b), but
the complexity and uncertainty of the information required are
major barriers. Physicians often bear the responsibility of
assessing the options on the patient’s behalf (Elstein et al,
2005), yet they are poor judges of patients’ preferences (Elstein
et al, 2004; Stalmeier et al, 2007).
Studies of patient preferences for treatment of LPC fall into three
classes: those which examine actual treatment choices (‘revealed
preferences’); those which estimate the value (‘utility’) of various
health states; and clinical decision analyses. Zeliadt et al (2006)
review the former class, whereas Bremner et al (2007) review the
latter two. Although the former help understand men’s decision
making processes, they provide limited insight into the relative
tolerability of side-effects because typically the information
presented to men at the point of decision-making is not
standardised. Studies in the latter classes typically quantify
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preferences in terms of utility decrements caused by specific
adverse effects (Lubeck et al, 2002; Bremner et al, 2007). Utility has
traditionally been estimated with time trade off and standard
gamble methods, and more recently with discrete choice experi-
ments (DCE) (Ryan, 2004). When hypothetical health states are
included in these ‘stated preference’ methods, they yield more
accurate and valid results than those based on personalised health
states because the description of health states is standardised
(Chapman et al, 1998).
To date, no studies have explicitly expressed patient preferences
for treatment of LPC in terms of the relative tolerability of adverse
treatment-related effects or the survival gains needed to make
persistent adverse effects worthwhile. Each of these is relevant to
clinicians counselling patients on treatment decisions, and the
latter perspective provides a benchmark against which emerging
evidence about actual survival benefits of alternative treatments
can be assessed. The aim of this study was to quantify these issues
using a DCE.
MATERIALS AND METHODS
Study design and sample
Data were obtained from the New South Wales (NSW) Prostate
Cancer Care and Outcomes Study (PCOS). PCOS is a population-
based (NSW, Australia) cohort study of men aged o70 when
diagnosed with prostate cancer and recruited from the NSW
Central Cancer Registry, and age and postcode matched controls
(without prostate cancer) recruited via the White Pages telephone
directory. Details of recruitment to PCOS and detailed demo-
graphic and clinical profiles of each treatment group and the
controls are reported elsewhere (Smith et al, 2009). Flow diagrams
for PCOS case and control recruitment and follow-up are given in
Supplementary Figures A and B. Sample flow relevant to this paper
is depicted in Figure 1. The study was approved by the ethics
committees of the Cancer Council NSW, Cancer Institute NSW and
NSW Department of Health. Informed consent was obtained from
each participant.








(n =433)‡      
† Figure A (online only) shows PCOS case  recruitment, participation and follow up to the
3 year interview. 
‡ Figure B (online only) shows PCOS control recruitment, participation and follow up to the
2 year interview  (controls were not interviewed at 3 years).
Ineligible: patient reported recurrent disease or
disease progression (n =99)  
Died or withdrawn as at 30 April 2005 (n =13) 
HRQOL sample (n =1381)
Initial management:
Active surveillance (n =166)
Radical prostatectomy (n =839)
External beam radiotherapy (EBRT) (n =106)
Androgen deprivation therapy (ADT) (n =37)
EBRT + ADT (n =136)
Low-dose-rate brachytherapy (n =56)
High-dose-rate brachytherapy (n =41)
Participants randomly sampled, stratified by treatment/control (n =459)
Participants consented to preference survey (n =440)
Participants eligible for preference survey (n =1814)
Refused consent (n =70)
Did not participate (n =18)
Preference sample (n =422)
Cases (localised prostate cancer) - initial management: 
Active surveillance (n =64)
Radical prostatectomy (n =66)
External beam radiotherapy (EBRT) (n =29)
Androgen deprivation therapy (ADT) (n =31)
EBRT + ADT (n =37)
Low-dose-rate brachytherapy (n =63)
High-dose-rate brachytherapy (n =66)
Controls (without prostate cancer) : (n =65)
Figure 1 Flow diagram showing derivation of HRQOL and preference survey samples of the PCOS.
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A DCE was used to determine the utility of hypothetical health
states that might result from treatment for LPC (Louviere et al,
2003). Each state was described in terms of ‘attributes’: treatment-
related adverse effects and survival. We reviewed the literature and
consulted with clinicians and a consumer representative to identify
seven common treatment-related adverse effects; each was
assigned three levels (Table 1). We also included average life
expectancy and its uncertainty, with levels 4, 8 or 12 years and
±25%, 50% or 75%, respectively.
Experimental design and sample size
Health states were constructed according to an experimental
design. The ‘full factorial’ design contains all possible combina-
tions of attributes and levels (39¼ 19 683 states). A statistically
optimal subsample of 108 health states was selected (Street et al,
2005), arranged into 54 pairs (‘choice sets’) (Supplementary Figure
C), then split into three versions (18 choice sets each). Twenty
respondents per treatment group per version were needed
(Louviere et al, 2000), thus 420 participants were required for
the preference survey.
Data collection
The preference survey was piloted (see technical Supplementary
Appendix for details). Preference survey participants were
randomly assigned to questionnaire version within treatment
strata. Preference surveys were posted to subjects, who were then
contacted by telephone and the data collected by telephone
interview. Collection of the health-related quality of life (HRQOL)
data is described elsewhere (Smith et al, 2009).
Analysis of the HRQOL data
Prevalence of urinary, sexual and bowel problems, fatigue and
other hormonal effects were estimated from the 3-year post-
diagnosis HRQOL data. Seven questions from the long-form
University of California Los Angeles Prostate Cancer Index (Litwin
et al, 1998) that most closely corresponded to the seven attributes
in the preference survey were used to classify each individual
(n¼ 1381) into one of the three categories (none, mild and severe)
for each treatment-related adverse effect (see technical Supple-
mentary Appendix for details).
Analysis of the preference data
Preference data were analysed with random parameter logit
models (McFadden and Train, 2000; Train, 2003) (see technical
Supplementary Appendix for details). In summary, the utility
impact of each treatment-related adverse effect level and survival
was inferred from respondents’ choices over the 54 pairs of
hypothetical health states. Two sets of coefficients were estimated,
one representing the mean utility impact of the attributes (fixed
effects), the other representing variation among individuals in
their preferences (random effects).
Relative tolerability of treatment-related adverse effects was
addressed by ranking the fixed effects coefficients: those with the
largest negative coefficients (greatest negative impact on utility)
were interpreted as least tolerable, and those with the smallest
negative coefficients or positive coefficients were interpreted as the
most tolerable. Confidence intervals on coefficients were taken into
account in interpreting the relative rankings.
The degree of variation among men in preferences was
quantified by the distribution of the random effect coefficients.
These are assumed to be normally distributed, so the majority
(68%) lie within one s.d. of the fixed effect coefficients. As this
Table 1 Treatment-related adverse effects included as attributes in the preference survey and their prevalence at 3-year follow-up in 1381 PCOS participants








Erectile dysfunction Base No problems achieving an erection when you want one 27 27
Mild Some problems achieving an erection when you want one 33 29
Severe Never able to achieve an erection when you want one 40 44
Loss of libido Base No change in sexual desire 8 7
Mild Less sexual desire 50 43
Severe Complete loss of sexual desire 41 51
Urinary leakage Base No problems with leaking urine 53 64
Mild Occasional problems with leaking urine 33 23
Severe Severe problems with leaking urine (no urinary control whatsoever) 14 12
Urinary blockage Base No problems with urine blockage 74 67
Mild Some problems with urine blockage (have a weak urine stream but get some
relief or comfort afterwards)
19 23
Severe Severe problems with urine blockage (continually feeling the need to urinate
but passing very little with no relief afterwards)
7 10
Bowel symptoms Base No bowel problems 79 75
Mild Occasional loose bowel movements with discomfort/pain 20 25
Severe Very frequent loose bowel movements with discomfort/pain and leakage 1 1
Fatigue Base No change in your energy level 47 44
Mild Some tiredness and loss of energy 49 51
Severe Severe tiredness and loss of energy 4 5
Hormonal effects Base No hot flushes or moodiness 88 85
Mild Mild hot flushes and moodiness 7 7
Severe Severe hot flushes and moodiness 5 8
Abbreviation: PCOS¼ Prostate Cancer Outcomes Study.
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represents the typical range of individual utility coefficients, it is a
clinically relevant expression of preference heterogeneity.
The effect of treatment group on preferences was evaluated by
estimating separate fixed effects models for each treatment group.
As parameter estimates in discrete outcome models are con-
founded by error variance (Swait and Louviere, 1993), parameter
estimates were not directly comparable across treatment groups.
Rank ordering of parameter estimates was used to assess the
similarity of preferences across the treatment groups, again taking
confidence intervals into consideration. The effect of age on
preferences for sexual function was addressed with a likelihood
ratio test for the interaction of age (dichotomised at 65) with
severe erectile dysfunction and severe loss of libido (see technical
Supplementary Appendix for details).
Estimation of survival gains needed
To estimate the survival gains needed to justify persistent
treatment-related adverse effects, the value of changes in health
utility associated with each level of each side effect was expressed
in terms of survival time (see technical Supplementary Appendix
for details). In summary, the survival gain needed to justify a
chronic treatment-related adverse effect(s) was such that the value
of this health state for this extended time (Tþ survival gain
needed) was equivalent to the value of the base case (health state
without treatment) for a survival time of 12 years (T). The base
case was determined from the 3-year post-diagnosis HRQOL data
of men initially managed with active surveillance; in the absence of
a randomised design, this group was deemed the most valid
comparator. The survival gains needed for the additional burden
of each persistent treatment-related adverse effect level singly and
for each commonly occurring combination of effects were
calculated, and their distributions were simulated. We report
medians and 2.5 and 97.5 centiles, analogous to 95% confidence
intervals estimated by bootstrap methods.
RESULTS
Study participants
Table 2 shows the characteristics of the 1381 PCOS cases with
complete 3-year HRQOL data (the ‘HRQOL sample’) and the 422
men, who participated in the preference survey (the ‘preference
sample’). Supplementary Figures A and B and Figure 1 show the
derivation of these samples.
Prevalence of adverse effects (Table 1) is given by treatment group
in Figure 2. Only 1.2% of the HRQOL sample (including 1.2% of the
active surveillance group) reported none of the seven side-effects/
symptoms 3 years after diagnosis. Prevalence of adverse effects for the
357 cases in the preference sample in also given Table 1. Severe
erectile dysfunction and severe loss of libido were common in both
the HRQOL sample and the DCE subsample, slightly moreso in the
latter because of stratified sampling by treatment.
Relative tolerability and preference heterogeneity are given in
Table 3. The rank order of treatment-related adverse effects was
similar across treatment groups (Supplementary Table A). Severe
urinary leakage, urinary blockage and bowel symptoms were the
three least tolerable side effects in five of the six treatment groups,
and in the active surveillance and control groups. There was no
effect of age on preferences: all interaction terms were non-
significant (P40.05), other estimates remained similar, and the
function value improved very little (2 log likelihood¼ 3.39,
df¼ 3, one-sided P¼ 0.34).
The majority (59%) of men initially managed with active
surveillance reported mild loss of libido at 3 years (Figure 2); this
was used as the base case. Additional survival needed to compensate
for persistent treatment-related adverse effect ranged from about 2
years for the severe levels of the three least tolerable treatment-
related adverse effects (both aspects of urinary function and bowel
problems), through to about 1 year for severe fatigue and other
Table 2 Characteristics of PCOS case participants who contributed
HRQOL data at 3-year follow-up (n¼ 1381) and PCOS cases and controls







n (% of 422)
Numbers per treatment strata
Cases (localised prostate cancer)
Radical prostatectomy 839 (46.3) 64 (15.2)
External beam radiotherapy (EBRT)
only
106 (5.8) 66 (15.6)
Androgen deprivation therapy (ADT)
only
37 (2.0) 37 (8.8)
Combined EBRT and ADT 136 (7.5) 64 (15.2)
Low-dose rate brachytherapy 56 (3.1) 31 (7.3)
High-dose rate brachytherapy 41 (2.3) 29 (6.9)
Active surveillance 166 (9.2) 66 (15.6)
Controls (without prostate cancer) 65 (15.4)
Age-group at 3-year follow-up or preference survey
o55 64 (4.6) 21 (5.0)
55–59 186 (13.5) 39 (9.2)
60–64 342 (24.8) 84 (19.9)
65–69 442 (32.0) 149 (35.3)
70–74 347 (25.1) 129 (30.6)
Mean (s.d.) age 65.0 (5.7) 65.9 (5.7)
Highest level of education
Less than high school certificate 57 (4.1) 20 (4.7)
Completed high school 953 (69.0) 290 (68.7)
University or college degree 364 (26.4) 110 (26.1)
Unknown 7 (0.5) 2 (0.5)
Marital status at diagnosis
Married or living as married 1160 (84.0) 350 (82.9)
Never married, divorced, separated or
widowed
217 (15.7) 72 (17.1)
Missing 4 (0.3) 0 (0.0)
Self reported health 3 year after diagnosis
Poor 66 (4.8) 11 (3.1)
Fair 176 (12.7) 55 (15.4)
Good 338 (24.5) 98 (27.5)
Very good 519 (37.6) 126 (35.3)
Excellent 275 (19.9) 64 (17.9)
Missing 7 (0.5) 3 (17.9)
PSA level at diagnosis (ngml1)
o4.0 140 (10.1) 35 (9.8)
4.0–9.9 799 (57.9) 163 (45.7)
10.0–19.9 282 (20.4) 87 (24.4)
20+ 129 (9.3) 65 (18.2)
Missing 31 (2.2) 7 (2.0)
Gleason score at diagnosis
2–5 135 (9.8) 36 (10.1)
6 651 (47.1) 151 (42.3)
7 465 (33.7) 120 (33.6)
8–9 114 (8.3) 47 (13.2)
Missing 16 (1.2) 3 (0.8)
Median months between diagnosis and preferences
survey (cases)
46 (32–60)
Median months between recruitment and
preferences survey (controls)
30 (27–50)
Abbreviations: HRQOL¼ health-related quality of life; PCOS¼ Prostate Cancer
Outcomes Study;PSA¼ prostate specific antigen.
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hormonal effects, about 10 months for mild other hormonal effects
and 3–6 months for the remainder (Figure 3).
Many men reported more than one adverse effect at 3 years.
There were 37¼ 2187 unique health states described by the three
levels of the seven adverse effects. It was not practicable to estimate
survival gains for each one. As the function used to calculate
survival gains needed (expression 4 in the technical Supplementary
Appendix) is not linear, the cumulative effect of multiple adverse
effects cannot be derived simply by summing over component
effects. We therefore simulated the survival gains needed for the
three most common treatment-related adverse effect profiles for
each treatment group (Supplementary Table B). Approximations
based on the simple sum of the component adverse effects in most
cases fell within the 2.5 and 97.5 centiles of the simulated
distributions. For example, severe erectile dysfunction alone would
be compensated by a 4-month survival benefit and severe libido
loss with 5.02 months (Figure 3), giving a sum of 9.02, which is a
reasonable approximation of the simulated estimate of 9.14
months, well within the 95% confidence interval (8.46–9.80,
Supplementary Table B).
DISCUSSION
Severe urinary dysfunction and bowel symptoms were least
tolerable, severe hormonal effects and fatigue were somewhat
more tolerable, and severe sexual dysfunction was relatively
benign, having about the same negative impact as mild urinary
dysfunction and bowel symptoms. Other hormonal effects were the
least tolerable of the mild treatment-related adverse effects. These
patterns were consistent across treatment groups and unaffected
by age. Overlaid on these aggregate results was substantial
variation in individual preferences, consistent with the decision
analysis of Sommers et al (2007) and two preference studies
(Singer et al, 1991; Stewart et al, 2005). Ours is the first study to
quantify this variation. This leads to two important observations.
First, virtually all men were averse to severe urinary leakage
(predominantly negative individual coefficients), although some
men’s aversion was much greater than others’. The same was true
for all severe adverse effects except severe loss of libido (where the
utility impact was consistently small across respondents). Second,







































































































Figure 2 Prevalence of urinary, sexual and bowel problems, fatigue and other hormonal effects 3 years after diagnosis by treatment group (HRQOL
sample, n¼ 1381): active surveillance (AS, n¼ 166), radical prostatectomy (RP, n¼ 839), external beam radiotherapy (EBRT, n¼ 106), ADT (n¼ 37),
combined therapy (EBRTþADT, n¼ 136), low-dose rate brachytherapy (LDRBT, n¼ 56), high-dose rate brachytherapy (HDRBT, n¼ 41). White¼ none,
grey¼mild, black¼ severe.
Table 3 Relative tolerability of treatment-related adverse effects (mean utility impact) and preference variability (range of individual utility coefficients)









coefficient (95% CI) P* MUI±1 s.d. P**
Severe urinary leakage 1.33 (1.49, 1.16) o0.001 2.21 0.44 o0.001
Severe bowel symptoms 1.23 (1.40, 1.07) o0.001 2.13 0.33 o0.001
Severe urinary blockage 1.08 (1.22, 0.93) o0.001 1.73 0.42 o0.001
Severe hormonal effects 0.63 (0.77, 0.49) o0.001 1.20 0.05 o0.001
Severe fatigue 0.62 (0.73, 0.50) o0.001 0.95 0.28 o0.001
Mild hormonal effects 0.43 (0.54, 0.31) o0.001 0.57 0.28 0.24
Severe erectile dysfunction 0.30 (0.43, 0.16) o0.001 1.17 0.58 o0.001
Mild urinary blockage 0.23 (0.35, 0.12) o0.001 0.37 0.09 0.40
Mild bowel symptoms 0.27 (0.38, 0.15) o0.001 0.32 0.21 0.69
Severe libido loss 0.21 (0.32, 0.10) o0.001 0.27 0.15 0.87
Mild urinary leakage 0.20 (0.31, 0.09) 0.001 0.30 0.09 0.56
Mild fatigue 0.14 (0.25, 0.03) 0.01 0.18 0.10 0.70
Mild erectile dysfunction 0.14 (0.02, 0.25) 0.025 0.08 0.19 0.60
Mild libido loss 0.04 (0.08, 0.15) 0.55 0.15 0.20 0.13
*, **P-value for test of null hypothesis that fixed (*) and random (**) parameter estimates are equal to zero. aThe mean ( bk in Equation 2 in Supplementary Appendix) reflects
the impact on utility of each attribute on average across respondents. bThe degree of variation among men in preferences (preference heterogeneity) was quantified with the s.d.
of the distribution of the $ki (see Equation 2 in technical Supplementary Appendix). Since the $ ki are normally distributed, the majority (68%) lie within one s.d. of the mean. This
range therefore represents the typical range of individual utility coefficients.
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severe urinary leakage, severe bowel symptoms and severe urinary
blockage was typically more negative than the upper end of the
range of decrements for most of the mild side effects (MUI±s.d. in
Table 3). Together, these two observations have an important
clinical implication: patients are likely to make decisions about
treatment based on severe adverse effects, not mild ones.
Men managed with active surveillance commonly experienced
mild loss of libido 3 years after diagnosis; this formed the base case
for estimating survival benefit. Severe erectile dysfunction and
severe loss of libido were prevalent, particularly in men who had
androgen deprivation therapy (ADT); 4 and 5 months additional
survival, respectively, were needed to justify these singly and about
9 months if experienced together. Urinary leakage was most
prevalent in the radical prostatectomy group; 4 months additional
survival was needed for mild levels and about 28 months for severe
levels. Mild bowel problems were most prevalent in men who had
external beam radiotherapy; about 6 months was needed to justify
these. Of the 18 most common health states 3-years post-diagnosis,
10 required o6 months of additional survival; the 4 health states
most common after radical prostatectomy were among these. For 6
of the 18 most common health states, survival benefits needed
ranged from 1–3 years; of these, 5 were relatively common in the
ADT group, accounting for 33.5% of that group in total. All
involved severe libido loss and severe erectile dysfunction,
accounting for about 9 months of the survival benefit needed.
Thus we found that relatively modest survival benefits were
sufficient to offset the most common side effects of treatments for
prostate cancer for about two-thirds of the most common health
states 3-years post-diagnosis. These are similar to those judged by
women with early breast cancer as sufficient to make adjuvant
chemotherapy or endocrine therapy worthwhile (Duric and
Stockler, 2001; Thewes et al, 2005). However, even substantial
survival benefits were insufficient to offset severe urinary
dysfunction, which is not rare (reported by 14% of our HRQOL
sample at 3 years, with similar prevalence estimates in other
population-based studies (Potosky et al, 2000, 2004; Sanda et al,
2008; Gore et al, 2009; Mols et al, 2009; Smith et al, 2009)). Men
considering their options should be counselled about the risks of
treatment-related adverse effects, their likely effects on quality of
life, and possible remedial measures.
The results of our study corroborate the findings of many utility
studies in LPC: mild symptoms have higher utility than severe, and
urinary and bowel symptoms have much lower utility than sexual
dysfunction and loss of libido (Bremner et al, 2007). Our study adds
to this literature by providing estimates of survival gains required for
each common adverse treatment effect, thereby translating utilities
into something practical for clinicians and patients—survival gains
needed to justify persistent problems. By incorporating the HRQOL
data from the our larger PCOS study, the current paper uniquely
reveals the potential overall impact of the trade-offs and survival
gains required for adverse treatment side effects.
Although there are numerous studies of patient preferences in
LPC prostate cancer, ours provides the most comprehensive set of
treatment-related adverse effects. Our population-based sample is a
major strength, containing experiences of all treatment options and
controls. Like many previous studies, ours was retrospective, with
men bringing personal experience to their hypothetical choices. We
avoided bias arising from patient’s preconceptions by not associat-
ing health states with treatments (Zeliadt et al, 2006). Although real
choices made before treatment may differ from hypothetical choices
made with the benefit of hindsight, arguably the latter are more
informative than the former for future men facing similar decisions.
Our controls were men of similar age and demographic profile to
our cases, and therefore most like men facing a primary treatment
decision. It is noteworthy that their results were similar to those of
each of the treatment groups (as shown in Supplementary Table A),
suggesting that men’s preferences are infact not markedly affected
by experience of treatment. We limited our sample of cases for the
DCE to men with localised disease as we felt their opinions were
most informative for men facing future choices about curative
treatments for LPC. The attitudes of patients whose disease
progressed, particularly those who died early because of very
aggressive disease, have not been captured in our study, and so our
results may not generalise to this group. Whether such patients
would have preferred to be alive even with severe adverse effects is a
question that is beyond the scope of this study.
Previous studies have various limitations: considering only one/
some adverse effects (Singer et al, 1991; Saigal et al, 2001; Bruner
et al, 2004); assigning different severity levels to adverse effects
(Saigal et al, 2001; Sculpher et al, 2004); assessing only one or two
treatment options (Singer et al, 1991; Bruner et al, 2004; Sculpher
et al, 2004; Jenkins et al, 2005); sampling respondents from only
one treatment type (Smith et al, 2002;Bruner et al, 2004);
combining bladder and bowel problems into one attribute
(Chapman et al, 1999; Knight et al, 2004); investigating just a
few hypothetical health states (Chapman et al, 1999; Saigal et al,
2001; Bruner et al, 2004; Knight et al, 2004; Jenkins et al, 2005); using
patients’ rating of their own health states (Smith et al, 2002; Krahn
et al, 2003). These factors limit the comparability of our results for
relative tolerability of adverse effects with those from other studies
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Figure 3 Additional months of life neededw to compensate for each persistent treatment-related adverse effect in excess of a base case of mild loss of
libido with no other problems and 12 year life expectancy.
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(Lubeck et al, 2002; Bremner et al, 2007). The best comparison is
with the pooled estimates from a meta-analysis (Bremner et al,
2007); taking severity into account, the ordering of sexual, urinary
and bowel dysfunction was as we observed. This ranking is
consistent with the observation that sexual dysfunction (although
relatively common) is not always correlated with sexual bother,
whereas poorer urinary and bowel function (although relatively rare)
are generally highly correlated with greater bother (Reeve et al, 2006;
Smith et al, 2009). The relative tolerability of these adverse effects in
this patient population may be influenced by baseline prevalence. In
particular, high prevalence of mild and severe erectile dysfunction
and loss of libido at baseline may contribute to these attributes being
assessed as more tolerable than less commonly experienced adverse
effects such as severe urinary and bowel problems.
To our knowledge, only three studies provide explicit estimates
of survival trade-offs for treatment for LPC. In one, men with
locally advanced prostate cancer were asked to make hypothetical
choices between short- and long-term ADT, involving the trade-off
of survival against sexual potency, hot flashes, fatigue and
osteoporosis (Wilke et al, 2010). On average, these men were
willing to trade 8% of a 5-year survival (4.8 months) for the better
sexual potency and sexual drive provided by the short- versus the
long-term ADT. In the second study, using a similar method but
involving only sexual potency and survival, men without prostate
cancer were willing to trade 10% of a 5-year survival (about 6
months) to maintain sexual potency (Singer et al, 1991). The results
from these two studies are not dissimilar to our estimates of 3
months of a 12-year life expectancy for mild erectile dysfunction
and 4 months for severe erectile dysfunction. The third study used
a DCE comprising six common adverse effects of ADT (hot flushes,
breast swelling or tenderness, physical energy, sex drive, ability to
maintain an erection and diarrhea; some with two levels, others
with three) and life expectancy (Sculpher et al, 2004). Survival
trade-offs were estimated by marginal rates of substitution (MRS)
between life expectancy and other attributes, showing for example
that 1.8 months of additional life expectancy was needed to move
from moderate to mild levels of diarrhoea or from mild to absent.
By contrast we found about 6 months was required to compensate
for occasional loose bowel movements. All of Sculpher et al’s (2004)
survival trade-off estimates were two to four times smaller than
ours. This is not because we used compensating variation (CV)
rather than MRS; MRS calculated from our data were 1.5 to 2 times
larger than our CV estimates, widening the difference with Sculpher
et al’s (2004). We suspect the main cause of difference in our
estimates arises from the way survival gain is expressed. The life
expectancy attribute in Sculpher et al’s (2004) DCE had only two
levels (2 and 4 months, framed as additional survival without
specifying the average life expectancy against which this gain is
assessed). Our life expectancy attribute had three levels (4, 8 and 12
years, framed as life expectancy, thus any calculated gain in life
expectancy is interpreted relative to this average). Despite this large
difference in time scale, the coefficients are not dissimilar: 0.23
(Sculpher et al, 2004) versus 0.34 (ours). Our survival benefit time
scale was realistic in terms of life expectancy of participants. Our
CV approach has several advantages: it allows for combinations of
adverse effects (more clinically relevant than single side effects); it
takes into account an empirically based base case and it quantifies
additional survival required to compensate for loss in quality of life
because of treatment (again with empirically based health states).
We found that mild erectile dysfunction had a significant positive
utility value (0.14, Table 3). This was probably because of the high
prevalence of severe erectile dysfunction in the DCE sample (44%,
Table 1). Although the positive utility impact of mild erectile
dysfunction can be explained, it can become problematic when added
to other negative utility effects. For example, our results paradoxically
suggest that severe libido loss requires 5.02 months survival gain,
whereas severe libido loss plus mild erectile dysfunction requires only
1.82 months. This empirical quirk should be kept in mind when
interpreting results in Supplementary Table B for heath states
including mild erectile dysfunction. It also highlights the potential
gains in utility of remedial measures for erectile dysfunction.
Increasing uptake of prostate-specific antigen testing and
attendant risks of overdiagnosis and overtreatment present clinical
and ethical dilemmas (Barry, 2009). If treated, men are at risk of
adverse treatment-related effects and a contestable survival benefit
(Potosky et al, 2004; Sanda et al, 2008; Gore et al, 2009; Mols
et al, 2009; Smith et al, 2009). The most fruitful avenues for future
research are therefore those that increase our understanding of
variation in individual preferences, the relationship of preferences to
treatment decisions and the effectiveness of different ways of
presenting complex choice information to men before treatment
decisions are made, of treatment innovations to minimise treatment-
related adverse effects and of early interventions to ameliorate them.
The ultimate goal is evidence-based shared decision making that
matches management and outcomes to patients’ preferences,
thereby maximising patient utility after diagnosis of LPC.
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